Scynexis (SCYX) Income from Non-Controlling Interests (2014)
Scynexis (SCYX) posted Income from Non-Controlling Interests of -$7.3 million for Q2 2014, down 162.2% on a QoQ basis from -$2.8 million in Q1 2014.
Scynexis (SCYX) Income from Non-Controlling Interests (2014) Analysis & Trends
Scynexis' Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at -$7.3 million for Q2 2014.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$7.3 million in Q2 2014, while the trailing twelve-month figure through Mar 2015 was -$7.3 million (changed N/A YoY) and the FY2014 annual result came in at -$10.1 million, changed N/A from the prior year.
- Income from Non-Controlling Interests was -$7.3 million for Q2 2014 at Scynexis, down from -$2.8 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$2.8 million in Q1 2014 and bottomed at -$7.3 million in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | - |
| 10 | Scynexis | 23.44 Mn | -13.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | -7.30 Mn |
| Mar 31, 2014 | -2.78 Mn |